Kardigan has raised $550.0M in total across 2 funding rounds.
Kardigan's investors include ARCH Venture Partners, Venrock.
Kardigan is a patient-driven heart health biopharmaceutical company modernizing cardiovascular drug development to deliver personalized medicines that advance patients beyond symptom management toward functional cures.[1][2][4] Founded in 2023 and based in South San Francisco, California, and Princeton, New Jersey, it develops a portfolio of late-stage candidates targeting underlying disease drivers like genetic dilated cardiomyopathy (DCM), calcific aortic valve stenosis (CAVS), and acute severe hypertension (ASH).[2][3][4][5] The company has raised over $554 million, including a $300 million Series A from Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage, followed by a $254 million Series B with additional investors like T. Rowe Price Investment Management.[1][3] With 56 employees and led by CEO Tassos Gianakakos, Kardigan leverages a cardiac intelligence platform integrating AI, real-world data, and proprietary tools to match treatments to patient responders, accelerating efficiency across programs.[1][4]
Kardigan serves patients with cardiovascular diseases—the leading global cause of death—by building a fully integrated R&D engine through discovery, in-licensing, and acquisitions.[1][3] Its growth momentum includes simultaneous advancement of three lead late-stage programs, integration of Prolaio’s AI platform for trial optimization, and active hiring in South San Francisco to expand its industry-leading team of former MyoKardia executives.[2][3][4]
Kardigan was founded in 2023 by Tassos Gianakakos, who serves as co-founder, CEO, and chair, alongside fellow former MyoKardia executives with proven track records in building transformative cardiovascular businesses.[1][2] The idea emerged from a vision to rethink drug development for heart health, addressing the field's stagnation in symptom management by targeting root causes with personalized approaches.[1][4] Launching with a $300 million Series A, Kardigan quickly curated a late-stage portfolio via strategic in-licensing and its discovery platform, marking early traction.[1][3]
Pivotal moments include the 2025 Series B raise of $254 million to propel its pipeline, affirming investor confidence in its data-driven model.[3] This capital-efficient build—powered by cardiac intelligence—positions Kardigan to deliver multiple medicines faster than traditional biopharma, humanizing its mission through a patient-first culture.[1][4][6]
Kardigan rides the AI-biotech convergence trend, applying cardiac-specific data platforms to cardiovascular disease—a $1 trillion+ market where innovation has lagged despite it being the top global killer.[1][4][5] Timing is ideal amid rising demand for precision medicine, post-pandemic heart health awareness, and AI tools reducing drug development costs by informing trial design.[3][4] Favorable forces include abundant real-world data, investor appetite for capital-efficient biopharma (evidenced by its rapid funding), and unmet needs in genetic heart conditions.[1][3]
By generating shared clinical insights across programs, Kardigan influences the ecosystem, accelerating cures and setting a model for integrated, data-powered cardio biopharma, potentially inspiring similar platforms in other therapeutic areas.[1][4]
Kardigan is poised to disrupt cardiovascular care by delivering first-in-class therapies from its pipeline, with near-term milestones in advancing DCM, CAVS, and ASH programs toward approval.[3][5] Trends like AI-driven personalization and multi-asset parallelism will shape its path, enabling faster iterations and expansions beyond current indications.[4] Its influence may evolve into a cardio innovation hub, licensing insights or acquiring assets to dominate preventable heart disease.
This positions Kardigan as a high-momentum player modernizing a critical field, fulfilling its launch vision of making cardiovascular disease curable and no longer the world's leading killer.[1][5]
Kardigan has raised $550.0M across 2 funding rounds. Most recently, it raised $250.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $250.0M Series B | ARCH Venture Partners, Venrock | |
| Jan 1, 2025 | $300.0M Series A | ARCH Venture Partners, Venrock |
